Ethyl 4-(13-chloro-6-nitro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)piperidine-1-carboxylate | 183482-80-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并环庚烷吡啶
• 英文名称: Ethyl 4-(13-chloro-6-nitro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)piperidine-1-carboxylate
• CAS: 183482-80-6
• 化学式: C₂₂H₂₄ClN₃O₄
• 分子量: 429.903
• InChiKey: VBLJWZFHIBWPFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  88.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Ethyl 4-(13-chloro-6-nitro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)piperidine-1-carboxylate 在 盐酸 、 氢溴酸 、 溴 、 铁粉 、 calcium chloride 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 反应 33.0h， 生成 6-Bromo-13-chloro-2-piperidin-4-yl-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
  参考文献：
  名称：

  Potent, Selective, and Orally Bioavailable Tricyclic Pyridyl Acetamide N-Oxide Inhibitors of Farnesyl Protein Transferase with Enhanced in Vivo Antitumor Activity

  摘要：

  We previously reported compound 1 as a potent farnesyl protein transferase (FPT) inhibitor that exhibited reasonable pharmacokinetic stability and showed moderate in vivo activity against a variety of tumor cell lines. The analogous C-11 single compound, pyridylacetamide 2, was found to be more potent than 1 in FPT inhibition. Further studies showed that modification of the ethano bridge of the tricyclic ring system by conversion into a double bond with concomitant introduction of a single bond at C-11 piperidine resulted in compound 3 that had superior FPT activity and pharmacokinetic stability. Compound 4, a 5-bromo-substituted analogue of 3, showed improved FPT activity, had good cellular activity, and demonstrated a remarkably improved pharmacokinetic profile with AUC of 84.9 and t(1/2) of 82 min. Compound 4 inhibited the growth of solid tumor in DLD-1 model by 70% at 50 mpk and 52% at 10 mpk.

  DOI：

  10.1021/jm980013b
• 作为产物：
  描述：

  8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDINYL)-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE 在 四丁基硝酸铵 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 14.0h， 生成 Ethyl 4-(13-chloro-6-nitro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  高度区域选择性的硝化反应提供了一种功能化的苯环庚啶三环系统功能化方法：在制备法呢基蛋白转移酶的纳摩尔抑制剂中的应用。

  摘要：

  已经对氮杂三环体系的硝化反应进行了全面的研究。在低温下使用KNO（3）-H（2）SO（4）进行经典硝化产生的硝化产物主要在9位，而使用硝酸四丁基铵-三氟乙酸酐（TBAN-TFAA）则只能硝化3-在氨基甲酸酯1和4-6以及三环酮7的情况下，这些位置是合适的。这些3-硝基三环衍生物是制备非常有效的法呢基蛋白质转移酶抑制剂（例如三环吡啶基乙酰胺32和其他新类似物）的有价值的中间体。

  DOI：

  10.1021/jo971100z

文献信息

• TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR
  申请人：Lansbury, JR. Peter T.

  公开号：US20110294794A1

  公开（公告）日：2011-12-01

  Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a therapeutically effective amount of a farnesyl transferase inhibitor, wherein the amount is effective to inhibit the farnesylation of a non-Ras FTase substrate involved in the autophagy pathway without substantially affecting the farnesylation of Ras or other oncology related substrates. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

  本发明提供了一种低剂量法尼醇转移酶抑制剂及其制药组合物，用于治疗蛋白病。这些低剂量低于最初设计这些化合物用于肿瘤治疗所使用的剂量。治疗包括向需要治疗的受体中注射治疗有效量的法尼醇转移酶抑制剂，其中该量能够有效抑制参与自噬通路的非Ras FTase底物的法尼酰化，而不会对Ras或其他与肿瘤相关的底物的法尼酰化产生明显影响。按照本发明的治疗方法还可以包括乙酰胆碱酯酶抑制剂、神经营养因子受体激活剂、NMDA拮抗剂、淀粉样沉积抑制剂、抗精神病药物、抗抑郁药物、抗焦虑药物或抗氧化剂。
• TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS
  申请人：SCHERING CORPORATION

  公开号：EP0929544B1

  公开（公告）日：2004-11-10
• Treatment of Lysosomal Storage Diseases
  申请人：Grammatopoulos Tom

  公开号：US20100184803A1

  公开（公告）日：2010-07-22

  Methods and compositions useful in the treatment or prevention of lysosomal storage diseases, such as Pompe's disease, Fabry's disease, Gaucher's disease, and Niemann-Pick disease, are provided. The treatment includes administering to a subject a farnesyl transferase inhibitor compound. The treatment may also include enzyme replacement therapy or gene therapy.
• [EN] TREATMENT OF LYSOSOMAL STORAGE DISEASES<br/>[FR] TRAITEMENT DES MALADIES DE SURCHARGE LYSOSOMALE
  申请人：LINK MEDICINE CORP

  公开号：WO2008112525A2

  公开（公告）日：2008-09-18

  (EN) Methods and compositions useful in the treatment or prevention of lysosomal storage diseases, such as Pompe's disease, Fabry's disease, Gaucher's disease, and Niemann-Pick disease, are provided. The treatment includes administering to a subject a farnesyl transferase inhibitor compound. The treatment may also include enzyme replacement therapy or gene therapy.(FR) Cette invention a trait à des procédés et des compositions utilisés dans le traitement ou la prévention des maladies de surcharge lysosomale, comme la maladie de Pompe, la maladie de Fabry, la maladie de Gaucher et la maladie de Niemann-Pick. Le traitement comprend l'administration chez un sujet d'un composé inhibiteur de farnésyl transférase. Le traitement peut également comprendre une enzymothérapie de remplacement ou une thérapie génique.
• [EN] TREATMENT OF SYNUCLEINOPATHIES<br/>[FR] TRAITEMENT DE SYNUCLÉINOPATHIES
  申请人：LINK MEDICINE CORP

  公开号：WO2008137692A1

  公开（公告）日：2008-11-13

  [EN] Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy, or other neurodegenerative diseases (e.g., amyotrophic lateral sclerosis, Huntington's disease, and Alzheimer's disease) are provided. The treatment including administering to a subject a farnesyl transferase inhibitor and an agent that inhibits the aggregation of a-synuclein (e.g., nortriptyline).
  [FR] L'invention concerne des procédés et des compositions servant au traitement ou à la prévention de synucléinopathies, telles que la maladie de Parkinson, la démence à corps de Lewy, l'atrophie systémique multiple ou d'autres maladies neurodégénératives (par exemple la sclérose latérale amyotrophique, la maladie d'Huntington et la maladie d'Alzheimer). Le traitement comprend l'administration à un sujet d'un inhibiteur de transférase de farnésyle et d'un agent qui empêche l'agrégation de l'a-synucléine (par exemple la nortriptyline).